LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

36.71 1.94

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

36.01

Max

37.5

Põhinäitajad
By Trading Economics
Sissetulek	11M 51M
Müük	39M 239M
P/E Sektori keskmine	11.36 110.024
Aktsiakasum	1.08
Kasumimarginaal	21.242
Töötajad	268
EBITDA	14M 73M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+31.21% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	24. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	387M 2.1B
Eelmine avamishind	34.77
Eelmine sulgemishind	36.71

Uudiste sentiment

By Acuity

50%

165 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. veebr 2026, 23:44 UTC

Kuumad aktsiad

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17. veebr 2026, 23:20 UTC

Tulu

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17. veebr 2026, 22:57 UTC

Tulu

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17. veebr 2026, 21:59 UTC

Tulu

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17. veebr 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17. veebr 2026, 23:54 UTC

Market Talk

Global Equities Roundup: Market Talk

17. veebr 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. veebr 2026, 23:45 UTC

Market Talk

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17. veebr 2026, 23:19 UTC

Tulu

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 23:15 UTC

Tulu

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 22:58 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17. veebr 2026, 22:58 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17. veebr 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17. veebr 2026, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17. veebr 2026, 22:44 UTC

Tulu

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 22:42 UTC

Tulu

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17. veebr 2026, 22:36 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17. veebr 2026, 22:36 UTC

Tulu

Santos Final Dividend 10.3 U.S. Cents/Security

17. veebr 2026, 22:36 UTC

Tulu

Santos FY Underlying Profit US$898 Million, Down 25%

17. veebr 2026, 22:35 UTC

Tulu

Santos FY Revenue US$4.94 Billion, Down 8%

17. veebr 2026, 22:35 UTC

Tulu

Correct: Santos FY Net Profit US$818 Million, Down 33%

17. veebr 2026, 22:35 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17. veebr 2026, 22:34 UTC

Tulu

Santos FY Net Profit US$818 Billion, Down 33%

17. veebr 2026, 22:02 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17. veebr 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. veebr 2026, 21:49 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17. veebr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17. veebr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

31.21% tõus

12 kuu keskmine prognoos

Keskmine 47.25 USD 31.21%

Kõrge 55 USD

Madal 42 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

165 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.